Menarini Group Presents New Data from the Phase 1b/2 ELEVATE Study of Elacestrant in Combination with Capivasertib in Patients with ER+, HER2- Metastatic Breast Cancer (mBC) at the 2026 American Society of Clinical Oncology (ASCO) Annual Meeting
Encouraging safety and preliminary efficacy analysis from the elacestrant and capivasertib Phase 1b…
AstraZeneca Collaborates with Roche Diagnostics Asia Pacific to Help Accelerate Sustainable Ecosystem for Advanced Pathology in Breast and Lung Cancer
SINGAPORE, May 18, 2026 /PRNewswire/ -- AstraZeneca and Roche Diagnostics Asia Pacific…
Underneat Launches ‘Check What’s Underneat’ Campaign to Make Breast Self-Examination a Monthly Habit
NEW DELHI, March 11, 2026 /PRNewswire/ -- Underneat, India's mass-premium shapewear brand co-founded…
Menarini Silicon Biosystems announces PACE trial biomarker analysis results confirming clinical utility of CELLSEARCH CTC enumeration to guide treatment decisions in a specific metastatic breast cancer subtype
The secondary analysis of the PACE trial highlights the value of counting…
Menarini Group Presents Elacestrant (ORSERDU) Phase 2 Combination Data in Patients with ER+, HER2- Metastatic Breast Cancer (mBC) at the 2025 San Antonio Breast Cancer Symposium
In addition, the expansive elacestrant clinical development program updates reinforce its potential as…
4D Paths Physics-Inspired QPOR Platform Predicts Neoadjuvant Chemotherapy Response from Routine Biopsy Images in Early-Stage Triple-Negative Breast Cancer from Phase II TBCRC-030 Trial
NEWTON, Mass., Dec. 03, 2025 (GLOBE NEWSWIRE) -- 4D Path, a company…
Ride for a Cause, Rally for a Cure: Manipal Hospital Yeshwanthpur Leads the Charge Against Breast Cancer
BENGALURU, India, Nov. 4, 2025 /PRNewswire/ -- The streets of Bengaluru turned…
SBI Life’s ‘Thanks-A-Dot’ sets a GUINNESS WORLD RECORDS, making breast health a living room conversation across communities
With a breast self-examination mosaic made of a record 1,191 'Hug of…
Tensive publishes positive long-term clinical follow-up data in Breast Cancer on REGENERA / SOFTAG breast implant
24-month Phase I follow-up data show positive outcomes are maintained High levels of…
NCCN Guidelines Navigator for Breast Cancer Genetic Testing and Treatment Debuts During Breast Cancer Awareness Month
The National Comprehensive Cancer Network expands interactive library of evidence-based, expert consensus-driven…
